Clinical Trials in Denver

Showing 5521-5540 of 18,161 trials

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

Prostatic Neoplasms, Castration-ResistantNeoplasms by Histologic TypeNeoplasms, Prostate+14 more

Poseida Therapeutics, Inc.40 participantsStarted Feb 2020

Duarte, California, United States • San Diego, California, United States • San Francisco, California, United States +7 more locations

Active Not RecruitingPhase 2< 1 mile

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

NCT01220583

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with chemotherapy or alone after surgery in treating salivary gland tumors. PURPOSE: This randomized phase II/III trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery.

Head and Neck Cancer

Radiation Therapy Oncology Group252 participantsStarted Jan 2011

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Gilbert, Arizona, United States +265 more locations

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Find Trials by Condition in Denver

Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

Neuroblastoma Precision Trial

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

INFINITY™Total Ankle Replacement Follow-up

Evaluation of the Phased Radio Frequency Ablation System

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Myeloma-Developing Regimens Using Genomics (MyDRUG)

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

COVID-19 Vaccine Response in Sickle Cell Disease

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

MCT for the Harvard/UCSF ROBIN Center

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients